While the Buy rating suggests confidence in HilleVax's fundamentals and potential growth, the reduction in the price target may reflect a reassessment of near-term price expectations, possibly due to market conditions or updated analysis of the company's prospects. This could lead to a neutral short-term impact on the stock as the positive sentiment from the Buy rating is counterbalanced by the lowered price target.